Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.72 |
| ▸ | KDR | P35968 | 10/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.72 |
| ▸ | FLT1 | P17948 | 4/20 | 0.72 |
| ▸ | FLT4 | P35916 | 3/20 | 0.72 |
| ▸ | SRC | P12931 | 5/20 | 0.68 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.67 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.67 |
| ▸ | CSK | P41240 | 1/20 | 0.67 |
| ▸ | TEK | Q02763 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1468087 | 0.84 | FGFR1 (0.98) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL14444614 | 0.84 | EGFR (0.59) | EGFRKDRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL27218199 | 0.84 | FGFR1 (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL5652837 | 0.83 | EGFR (0.87) | EGFRKDRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL1467744 | 0.83 | FGFR1 (0.98) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL3677717 | 0.83 | KDR (0.88) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL13604770 | 0.83 | EGFR (0.80) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL17520338 | 0.83 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL12012 | 0.83 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL19006870 | 0.83 | EGFR (0.81) | EGFRKDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | KDR, FLT1, FLT4 | EGFR 439/4885KDR 1/4885FGFR1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.